share_log

Roth Capital Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $90

Benzinga Real-time News ·  Dec 23, 2022 07:44

Roth Capital analyst Scott Henry maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $85 to $90.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment